Search Results for “ breast cancer ” – Page 29 – media

Study Unravels New Protein Complex that Repairs Broken DNA Ends

In a major breakthrough in cancer research, a team of scientists from the University of Toronto, The Institute of Cancer Research, London, The Netherlands Cancer Institute and the University of Bern have discovered how cells repair damaged strands of DNA. They revealed a brand new protein complex in cells that protect broken DNA ends and causes its repair, in their study published in Nature on Wednesday.
- Source: News Medical
- 826
- July 23, 2018
cancer DNA Researches
Two Approvals for AstraZeneca in Japan

The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
- Source: Reuters
- 1,000
- July 3, 2018
breast cancer Japan lung cancer New Approvals
Click-To-Release Chemotherapy – A Novel Approach

Tagworks Pharmaceuticals, based at Radboud University Medical Center, have developed a novel technique for the targeted delivery of ADCs to treat tumors. By the controlled 'click-to-release' of the chemotherapy drug from its tumor-binding carrier, the treatment would reach the right location.
- Source: Ddu
- 505
- May 23, 2018
cancer Researches
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 606
- May 14, 2018
biotech Company Insights IPO
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival (PFS), which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
- Source: finance.yahoo
- 681
- April 10, 2018
Clinical Trials keytruda Merck NSCLC
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna® (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
- Source: Novartis
- 631
- March 29, 2018
FDA New Approvals Ph+ CML-CP Tasigna®
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA Priority Review designation; provides clinicians with pediatric-specific safety and clinical data Novartis continues commitment to people living with CML, including pediatric patients with this cancer
- Source: novartis
- 639
- March 26, 2018
chronic myeloid leukemia Clinical Trials FDA Tasigna®
How Precision Medicine is breaking off Chokehold on Healthcare with Big Data

Big data is showering its miraculous effects on a range of industries. And the healthcare industry is not left out of the bandwagon. Precision medicine is at the brink of a revolution in individualizing treatment, and healthcare professionals are devising ways to prevent and treat diseases with granularity down to a single patient’s genome.
- Source: dexlabanalytics
- 538
- February 23, 2018
big data healthcare Researches
Augmented Reality Helps Surgeons ‘See Through’ Tissue & Reconnect Blood Vessels

Surgeons use Microsoft HoloLens headsets while operating on patients undergoing reconstructive lower limb surgery.
- Source: ODT
- 582
- February 2, 2018
augmented reality medical device Researches surgery
Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
- Source: Biospace
- 460
- February 1, 2018
Cascadian HER2 Market Views merger-and-acquisition

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.